{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:16:14Z","timestamp":1783419374518,"version":"3.54.6"},"reference-count":96,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Sarcoidosis is a multisystem disease characterised by a heterogeneous clinical presentation and variable disease course. Despite low mortality, the burden of sarcoidosis extends beyond organ involvement, with many patients reporting significant impairment in quality of life (QoL). Fatigue, chronic cough, and small fibre neuropathy (SFN) are among the most prevalent and debilitating symptoms reported by patients, often demonstrating poor correlation with conventional markers of disease activity and frequently persisting despite apparent disease control. This review examines the impact of sarcoidosis on QoL and highlights the limitations of traditional assessment tools, including imaging and pulmonary function testing, in capturing the full extent of disease burden. The role of patient-reported outcome measures (PROMs) is discussed, including generic instruments and sarcoidosis-specific tools such as the King\u2019s Sarcoidosis Questionnaire (KSQ), Sarcoidosis Health Questionnaire (SHQ), and Sarcoidosis Assessment Tool (SAT), alongside symptom-specific measures targeting fatigue, neuropathic symptoms, and cough. Current and emerging management strategies aimed at improving QoL are reviewed, including immunosuppressive therapies, biologic agents, and non-pharmacological interventions. Despite increasing recognition of QoL as a key outcome, its integration into clinical trials remains inconsistent. Incorporating PROMs into routine clinical practice and research is essential to enable comprehensive assessment and support patient-centred care. Greater emphasis on QoL outcomes may improve therapeutic decision-making and overall disease management in sarcoidosis.<\/jats:p>","DOI":"10.3390\/diagnostics16132079","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:48:32Z","timestamp":1782992912000},"page":"2079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of Life in Sarcoidosis"],"prefix":"10.3390","volume":"16","author":[{"given":"Evelyn","family":"Lynn","sequence":"first","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy\u2019s and St Thomas\u2019s Foundation Trust, Sydney Street, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0528-685X","authenticated-orcid":false,"given":"James","family":"Tadjkarimi","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy\u2019s and St Thomas\u2019s Foundation Trust, Sydney Street, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valencia","family":"Lim","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy\u2019s and St Thomas\u2019s Foundation Trust, Sydney Street, London SW3 6NP, UK"},{"name":"Division of Respiratory and Critical Care Medicine, University Medicine Cluster, National University Hospital, Singapore 119077, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-0928","authenticated-orcid":false,"given":"Vasileios","family":"Kouranos","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy\u2019s and St Thomas\u2019s Foundation Trust, Sydney Street, London SW3 6NP, UK"},{"name":"National Heart & Lung Institute, Imperial College London, London SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Seve, P., Pacheco, Y., Durupt, F., Jamilloux, Y., Gerfaud-Valentin, M., Isaac, S., Boussel, L., Calender, A., Androdias, G., and Valeyre, D. (2021). Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells, 10.","DOI":"10.3390\/cells10040766"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Herrero-Morant, A., Fernandez-Ramon, R., Prieto-Pena, D., Martin-Varillas, J.L., Castaneda, S., and Blanco, R. (2025). Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain. Biomedicines, 13.","DOI":"10.3390\/biomedicines13061360"},{"key":"ref_4","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101283","DOI":"10.1016\/j.lanepe.2025.101283","article-title":"Incidence, prevalence, and mortality of sarcoidosis in England: A population-based study","volume":"53","author":"Bechman","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108049","DOI":"10.1016\/j.rmed.2025.108049","article-title":"Prevalence, incidence, and mortality associated with sarcoidosis over three decades in the HUNT Study in Norway","volume":"241","author":"Lunde","year":"2025","journal-title":"Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","article-title":"Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: Insights from the Global Burden of Disease Study 2021","volume":"25","author":"Cen","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cao, J., Li, H., Yin, X., Yang, J., Pu, L., and Yang, J. (2025). Global burden of pulmonary sarcoidosis from 1990 to 2021: A comprehensive analysis based on the GBD 2021 study. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1585005"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e002461","DOI":"10.1136\/bmjresp-2024-002461","article-title":"National retrospective registry survey on the epidemiology of sarcoidosis in Finland 2002\u20132022","volume":"11","author":"Salonen","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106564","DOI":"10.1016\/j.rmed.2021.106564","article-title":"The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study","volume":"187","author":"Zhou","year":"2021","journal-title":"Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hena, K.M. (2020). Sarcoidosis Epidemiology: Race Matters. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.537382"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1164\/rccm.201906-1250OC","article-title":"Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis","volume":"201","author":"Harper","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/a-2716-5737","article-title":"Immunopathogenesis of Sarcoidosis","volume":"46","author":"Vagts","year":"2025","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1465-9921-11-25","article-title":"Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients","volume":"11","author":"Grunewald","year":"2010","journal-title":"Respir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1055\/s-0034-1376860","article-title":"Genetics of sarcoidosis","volume":"35","author":"Fischer","year":"2014","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/jmedgenet-2013-101532","article-title":"Recent advances in the genetics of sarcoidosis","volume":"50","author":"Spagnolo","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1164\/rccm.2112060","article-title":"The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans","volume":"167","author":"Rybicki","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.201507-1372OC","article-title":"High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences","volume":"193","author":"Rivera","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/cei.13635","article-title":"Adaptive immune system in pulmonary sarcoidosis-Comparison of peripheral and alveolar biomarkers","volume":"205","author":"Bergantini","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: A multicenter real-world analysis","volume":"23","author":"Sakkat","year":"2022","journal-title":"Respir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1183\/09031936.03.00083002","article-title":"Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis","volume":"21","author":"Fehrenbach","year":"2003","journal-title":"Eur. Respir. J."},{"key":"ref_24","first-page":"49","article-title":"Localization of the immune response in sarcoidosis","volume":"120","author":"Hunninghake","year":"1979","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.it.2020.01.007","article-title":"Sarcoidosis and the mTOR, Rac1, and Autophagy Triad","volume":"41","author":"Pacheco","year":"2020","journal-title":"Trends Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"Drent","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neubiorev.2008.10.005","article-title":"Evidence for a cytokine model of cognitive function","volume":"33","author":"McAfoose","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1474-4422(04)00805-1","article-title":"Neurosarcoidosis: A clinical dilemma","volume":"3","author":"Hoitsma","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-5728(90)90145-D","article-title":"In vitro studies on the characterization of cellular proliferation following neuronal injury in the adult rat brain","volume":"29","author":"Katz","year":"1990","journal-title":"J. Neuroimmunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/brbi.2000.0613","article-title":"Cytokine-induced sickness behavior: Where do we stand?","volume":"15","author":"Dantzer","year":"2001","journal-title":"Brain Behav. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12974-017-0796-7","article-title":"Interleukin-1 as a mediator of fatigue in disease: A narrative review","volume":"14","author":"Roerink","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbi.2011.06.004","article-title":"Reduced Th2 cytokine production by sarcoidosis patients in clinical remission with chronic fatigue","volume":"25","author":"Korenromp","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1752-699X.2010.00214.x","article-title":"Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis","volume":"5","author":"Baydur","year":"2011","journal-title":"Clin. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"190145","DOI":"10.1183\/16000617.0145-2019","article-title":"Clinical phenotyping: Role in treatment decisions in sarcoidosis","volume":"29","author":"Baughman","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","article-title":"Sarcoidosis-related mortality in the United States from 1988 to 2007","volume":"183","author":"Swigris","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"00141-2018","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: Patient treatment priorities","volume":"4","author":"Baughman","year":"2018","journal-title":"ERJ Open Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00408-018-0144-4","article-title":"Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners","volume":"196","author":"Moor","year":"2018","journal-title":"Lung"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-019-00206-7","article-title":"The Burden of Sarcoidosis Symptoms from a Patient Perspective","volume":"197","author":"Voortman","year":"2019","journal-title":"Lung"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.130.4.989","article-title":"Fatigue is associated with quality of life in sarcoidosis patients","volume":"130","author":"Michielsen","year":"2006","journal-title":"Chest"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1055\/s-0030-1262216","article-title":"Quality of life in sarcoidosis: Assessment and management","volume":"31","author":"Lower","year":"2010","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MCP.0b013e32832d0403","article-title":"Fatigue in sarcoidosis: A systematic review","volume":"15","author":"Lower","year":"2009","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"16921","DOI":"10.2147\/JIR.S549445","article-title":"Peripheral Levels of Selected Biomarkers in Patients with Post-Sarcoidosis Chronic Fatigue Syndrome","volume":"18","author":"Baczek","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"ref_48","first-page":"139","article-title":"Anxiety and depression in sarcoidosis: The influence of age, gender, affected organs, concomitant diseases and dyspnea","volume":"29","author":"Hinz","year":"2012","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11916-011-0180-8","article-title":"Sarcoidosis and small-fiber neuropathy","volume":"15","author":"Tavee","year":"2011","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rmed.2010.09.014","article-title":"The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis","volume":"105","author":"Hoitsma","year":"2011","journal-title":"Respir. Med."},{"key":"ref_52","first-page":"333","article-title":"Determination of the smallest detectable change (SDC) and the minimal important difference (MID) for the Small Fiber Neuropathy Screening List (SFNSL) in sarcoidosis","volume":"35","author":"Voortman","year":"2018","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.0b013e3181bacf05","article-title":"Intraepidermal nerve fiber density and its application in sarcoidosis","volume":"73","author":"Bakkers","year":"2009","journal-title":"Neurology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1038\/s41598-018-23107-w","article-title":"Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy","volume":"8","author":"Brines","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.sleep.2014.12.025","article-title":"Subjective sleep quality in sarcoidosis","volume":"16","author":"Wirtz","year":"2015","journal-title":"Sleep. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MCP.0b013e3283547092","article-title":"Psychological stress in sarcoidosis","volume":"18","author":"Wilsher","year":"2012","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/diagnostics11061089","article-title":"Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes","volume":"11","author":"Saketkoo","year":"2021","journal-title":"Diagnostics"},{"key":"ref_58","first-page":"158","article-title":"Predictors of cough-specific and generic quality of life in sarcoidosis patients","volume":"37","author":"Gvozdenovic","year":"2020","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1440-1843.2012.02134.x","article-title":"Validation of the Sarcoidosis Health Questionnaire in a non-US population","volume":"17","author":"Wilsher","year":"2012","journal-title":"Respirology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccm.2023.09.002","article-title":"Biomarkers in Sarcoidosis: Beginning of a New Era?","volume":"45","author":"Bajnath","year":"2024","journal-title":"Clin. Chest Med."},{"key":"ref_61","first-page":"16824","article-title":"Use of fatigue assessment scale and small fiber neuropathy screening list in Japanese patients with sarcoidosis","volume":"42","author":"Tomioka","year":"2025","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_62","first-page":"127","article-title":"The relationship between fatigue and clinical parameters in pulmonary sarcoidosis","volume":"21","author":"Drent","year":"2004","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_63","first-page":"2","article-title":"Patient reported outcome measures (PROMs) in sarcoidosis","volume":"34","author":"Thunold","year":"2017","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the Treatment of Pulmonary Sarcoidosis","volume":"163","author":"Culver","year":"2023","journal-title":"Chest"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2300198","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: A randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s11136-025-03950-x","article-title":"COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures: Version 2.0","volume":"34","author":"Gagnier","year":"2025","journal-title":"Qual. Life Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","article-title":"Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure","volume":"191","author":"Judson","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1513\/AnnalsATS.202006-607OC","article-title":"Evaluating the Minimal Clinically Important Difference of the King\u2019s Sarcoidosis Questionnaire in a Multicenter Prospective Study","volume":"18","author":"Baughman","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_70","first-page":"17859","article-title":"WASOG Clinical Trial Endpoint Task Force: Executive Summary","volume":"42","author":"Baughman","year":"2025","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George\u2019s Respiratory Questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jval.2013.10.006","article-title":"From translation to version management: A history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire","volume":"17","author":"Rabin","year":"2014","journal-title":"Value Health"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MCP.0000000000001203","article-title":"PROMs in sarcoidosis\u2014What to use for systemic disease and individual organs and why?","volume":"31","author":"Ravaglia","year":"2025","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_74","first-page":"e2023002","article-title":"Validation of the Turkish Version of the Sarcoidosis Health Questionnaire: A cross-sectional study","volume":"40","author":"Kavas","year":"2023","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102720","DOI":"10.1016\/j.coi.2025.102720","article-title":"Optimizing patient-reported outcomes for sarcoidosis","volume":"99","author":"Kahlmann","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1164\/rccm.200211-1343OC","article-title":"The Sarcoidosis Health Questionnaire: A new measure of health-related quality of life","volume":"168","author":"Cox","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King\u2019s Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2019.01.001","article-title":"Can the Sarcoidosis Health Questionnaire predict the long-term outcomes in Japanese sarcoidosis patients?","volume":"149","author":"Tanizawa","year":"2019","journal-title":"Respir. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1590\/S1806-37562015000000063","article-title":"Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia","volume":"42","author":"Gvozdenovic","year":"2016","journal-title":"J. Bras. Pneumol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2500943","DOI":"10.1183\/13993003.00943-2025","article-title":"Pulmonary sarcoidosis clinical trial end-points: A Delphi study","volume":"66","author":"Baughman","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_81","first-page":"RCT5337","article-title":"Late Breaking Abstract\u2014EFZO-FIT, the largest ever interventional trial in pulmonary sarcoidosis","volume":"66","author":"Culver","year":"2025","journal-title":"Eur. Respir. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: The Fatigue Assessment Scale (FAS)","volume":"9","author":"Michielsen","year":"2004","journal-title":"Br. J. Health Psychol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3999(02)00392-6","article-title":"Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale","volume":"54","author":"Michielsen","year":"2003","journal-title":"J. Psychosom. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"ref_85","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: Wells Law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(22)00387-3","article-title":"Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): A randomised controlled trial","volume":"11","author":"Kahlmann","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","author":"Lower","year":"2008","journal-title":"Chest"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: A double-blind, placebo-controlled, crossover trial","volume":"45","author":"Lower","year":"2013","journal-title":"J. Pain Symptom Manag."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MCP.0000000000001191","article-title":"Small fibre neuropathy and sarcoidosis, target for diagnosis and treatment?","volume":"31","author":"Atkins","year":"2025","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_91","first-page":"e2022033","article-title":"Infliximab decreases inflammatory activity but has no effect on small fiber neuropathy related symptoms in Dutch patients with sarcoidosis","volume":"39","author":"Raasing","year":"2022","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2119\/molmed.2013.00122","article-title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","volume":"19","author":"Dahan","year":"2013","journal-title":"Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1212\/WNL.0000000000211412","article-title":"Sarcoidosis-Associated Small Fiber Neuropathy Responsive to Tocilizumab: A Case Series","volume":"104","author":"Stern","year":"2025","journal-title":"Neurology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/thorax-2025-223014","article-title":"Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis","volume":"80","author":"Bechman","year":"2025","journal-title":"Thorax"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"210026","DOI":"10.1183\/16000617.0026-2021","article-title":"Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: Where to go from here?","volume":"30","author":"Kalluri","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MCP.0000000000001085","article-title":"Leveraging AI technology in sarcoidosis","volume":"30","author":"Premjee","year":"2024","journal-title":"Curr. Opin. Pulm. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/2079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:46:46Z","timestamp":1783417606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/13\/2079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":96,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["diagnostics16132079"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16132079","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}